Skip to content
Peptide research

Svetinorm

Also known as Liver Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

Svetinorm is a liver-derived bioregulator peptide marketed to aid liver regeneration in hepatitis, chemo recovery, and general liver strain. Benefits remain unproven, despite an internal report describing human outcomes. It is not a substitute for medical treatment, and mild allergy to the material is possible. It is not FDA-approved; it is sold internationally as a dietary supplement, and unregulated products sold online vary in quality.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Svetinorm is a natural peptide bioregulator containing peptide complex A-7, derived from liver tissue of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets the liver, where it is designed to restore hepatocyte metabolism and normalize liver cell functional activity. The peptides have a molecular weight up to 10,000 Da and possess tissue-specific action on liver cells.

A clinical study conducted at the St. Petersburg Institute of Bioregulation and Gerontology compared 47 patients with chronic hepatitis or after chemotherapy for cancer (ages 35-68, disease duration 3-10 years) receiving Svetinorm plus standard therapy against 38 controls on standard therapy alone. Most patients reported elimination of fatigue, improved appetite and working capacity, and 53% experienced considerable decrease in pain syndrome. Biochemical markers including bilirubin, ALT, and immunoglobulin levels showed improvement.

Svetinorm is positioned as a hepatoprotective supplement for chronic liver conditions, post-chemotherapy recovery, chronic intoxication, and age-related liver function decline. It is manufactured in capsule form and is available as a dietary supplement.

How it works in the body

A bioregulator peptide complex derived from liver tissue that regulates hepatocyte gene expression. It promotes the synthesis of liver-specific proteins involved in detoxification, bile production, and metabolic processing, supporting liver regeneration and function.

Research overview

Svetinorm has a formal clinical study report from the St. Petersburg Institute covering 47 treatment patients and 38 controls. The study included two groups: chronic persisting hepatitis patients (34 total, ages 35-56) and post-chemotherapy oncological patients (13 total, ages 53-68). Treatment duration was 15-20 days at 2 capsules twice daily. The report describes symptom improvement and biochemical changes from baseline; it does not establish statistically significant superiority over standard treatment. The study concluded with evidence of hepatoprotective properties and recommended Svetinorm for complex treatment of acute and chronic liver disorders. Additional supporting literature comes from Jay Campbell's health education platform describing the mechanism as enhancing cellular resilience and regeneration.

Who researches Svetinorm?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching liver health

    Studied for hepatoprotective effects or liver function support.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(2)

Rated by level of concern

  • Allergic reaction to bovine liver-derived peptides

    Low

    Class/mechanism reasoning only; no FDA-approved labeling and no adverse-event database entry exists for Svetinorm

  • Not a substitute for medical liver treatment

    High

    Standard hepatology practice (AASLD-IDSA HCV guidance; EASL clinical practice guidelines); no regulatory approval for Svetinorm as a therapy

Interaction summary(7)

Rated by direction with this peptide

  • Direct-acting antivirals / interferon for hepatitis B or C

    CautionModerate

    No pharmacologic interaction is documented or studied. The risk is substitution, not chemistry: using a bioregulator instead of, or as a reason to delay, curative antiviral therapy is the main plausible harm pathway in chronic hepatitis. Severity is set at Moderate to reflect the magnitude of that missed-treatment harm, not any demonstrated drug-drug effect.

    AASLD-IDSA / EASL hepatitis treatment guidance; no interaction study exists

  • Cytotoxic chemotherapy (e.g., methotrexate, anthracyclines, platinum agents)

    CautionTheoretical

    A preparation marketed as promoting hepatocyte regeneration has never been tested for effects on chemotherapy efficacy, hepatic drug clearance, or tumor biology, so co-use during active oncology treatment should be cleared with the treating oncologist.

    No published interaction data; mechanism-based inference only

  • Hepatotoxic drugs (acetaminophen, isoniazid, amiodarone, high-dose statins)

    CautionTheoretical

    Animal data on related liver peptide complexes suggest antioxidant/hepatoprotective effects, but nothing establishes this in humans, and any perceived protection could mask rising transaminases and delay recognition of real drug-induced liver injury. Listed as Caution rather than Protective for that reason.

    PMID 32362099 (animal hepatoprotection, related compounds); masking risk is clinical inference

  • Alcohol

    CautionModerate

    Not a pharmacologic interaction. Continued alcohol use is the dominant driver of progression in most liver disease and is not offset by any supplement; a hepatoprotective claim should never be treated as license to keep drinking.

    Standard hepatology practice

  • Narrow-therapeutic-index drugs cleared hepatically (warfarin, tacrolimus, phenytoin)

    CautionTheoretical

    Entirely conditional: if the claimed enhancement of hepatocyte synthetic and detoxification capacity were real, hepatic clearance and clotting-factor synthesis could shift enough to change INR or trough levels. Unstudied in humans, so monitor rather than assume no effect — but note there is no evidence the underlying effect occurs at all.

    Mechanism-based extrapolation; no human PK data

  • Immunosuppressants after liver transplant

    CautionTheoretical

    The related liver peptide literature reports immunomodulatory effects in animal models, which is an unwanted and unquantified variable in a patient whose graft depends on controlled immunosuppression. No human immunologic data exist.

    PMID 32362099 (immune status normalization reported in animal models of related peptides)

  • Ursodeoxycholic acid

    NeutralLow

    No documented or plausible interaction. UDCA has real trial evidence in cholestatic liver disease and should be dosed on its own merits, with the peptide adding no demonstrated benefit on top.

    No interaction data located

Known risks(2)

  • Allergic reaction to bovine liver-derived peptides

    Low

    No serious adverse events reported in the clinical study.

  • Not a substitute for medical liver treatment

    Important

    Svetinorm is a dietary supplement and should not replace medical treatment for serious liver conditions including viral hepatitis, cirrhosis, or liver failure.

Drug interactions(2)

  • Hepatotoxic medications (acetaminophen, statins, etc.)

    Theoretical benefit as hepatoprotective; no documented interaction

  • Antiviral medications for hepatitis

    Used concurrently in Russian clinical practice; no documented antagonism

Research & benefits

Evidence base

Evidence Level
Limited Evidence
Total Studies
3
Human Studies
85

Svetinorm has a formal clinical study from the Khavinson Institute testing 47 patients against 38 controls, which is among the better-documented bioregulator studies. Results showed hepatoprotective effects in chronic hepatitis and post-chemotherapy patients with improvements in both subjective symptoms and biochemical markers. However, the study was open-label, conducted at a single center, and has not been replicated outside Russia.

Researched for(4)

Rated by confidence in the evidence

  • Hepatoprotective effects in chronic hepatitis

    Speculative

    An internal human report studied Svetinorm; benefit remains uncertain.

    PMID 32362099 (Adv Gerontol 2020;33(1):159-164, review of polypeptide liver complex Ventvil + tetrapeptide KEDA/Livagen); it does not study Svetinorm

  • Improved liver function markers (bilirubin, ALT reduction)

    Speculative

    An internal human report includes bilirubin and ALT measurements; efficacy remains unconfirmed.

    PMID 32362099 (animal/in vitro, general liver-function language only); no trial registration identified for Svetinorm

  • Post-chemotherapy liver recovery support

    Speculative

    An internal report includes 13 post-chemotherapy patients; benefit remains uncertain.

    No primary source located; indirect extrapolation from PMID 32362099 animal hepatitis/fibrosis models

  • Reduced fatigue and improved appetite in liver disease patients

    Speculative

    Uncontrolled observational reports only, no peer-reviewed or blinded human data exist.

    No peer-reviewed human trial identified; claim not supported by PMID 32362099

Benefits(4)

  • Hepatoprotective effects in chronic hepatitis

    Khavinson Institute clinical study (47 patients + 38 controls)

  • Improved liver function markers (bilirubin, ALT reduction)

    Khavinson Institute clinical study (Oct 2003 - Jan 2004)

  • Post-chemotherapy liver recovery support

    Khavinson Institute clinical study (13 oncological patients)

  • Reduced fatigue and improved appetite in liver disease patients

    Khavinson Institute clinical study subjective outcomes

Key studies(1)

  1. Clinical study of the biologically active peptide bioregulator Svetinorm

    Open-label clinical studyn=47 treatment + n=38 control15-20 days

    Khavinson VKh et al.

    St. Petersburg Institute of Bioregulation and Gerontology (internal report)

    2004

    Hepatoprotective effects demonstrated in chronic hepatitis and post-chemotherapy patients. Most patients showed improved symptoms (fatigue, appetite, pain) and biochemical markers (bilirubin, ALT, immunoglobulin levels).

Regulation & availability

Why researchers look at it

Svetinorm targets liver cell metabolism with organ-specific peptides from young calf liver. Its clinical study in chronic hepatitis and post-chemotherapy patients showed improved liver markers, making it one of the better-documented Khavinson bioregulators for liver support.

Estimated cost
$30-60/mo (capsules)
FDA status
Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
WADA status
Not listed on WADA Prohibited List; not evaluated by WADA
Prescribability
Available in Russia as dietary supplement; not approved in USA/EU
Availability
Not available through conventional pharmacies in the USA or EU.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(2)

  1. 2003-2004
    Clinical study conducted at St. Petersburg Institute (Oct 2003 - Jan 2004)
  2. 2000s
    Commercialized as Cytomaxes dietary supplement in Russia

Sources & FAQs

Research sources(1)

Frequently asked questions(3)

What liver conditions can Svetinorm be used for?

Svetinorm has been studied in chronic persisting hepatitis and post-chemotherapy liver recovery. It is marketed for chronic liver conditions, detoxification support, chronic intoxication, and age-related liver function decline.

How does Svetinorm differ from traditional liver supplements like milk thistle?

Svetinorm uses organ-specific peptides that are theorized to directly regulate hepatocyte metabolism through peptide-DNA interactions, rather than providing antioxidant or anti-inflammatory botanical compounds. The mechanisms are different.

How long do the effects of Svetinorm last?

According to Khavinson bioregulator theory, effects accumulate during treatment and persist for 3-6 months.